Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 19/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 19/20 | 1.00 |
| ▸ | ABL1 | P00519 | 3/20 | 1.00 |
| ▸ | BMX | P51813 | 3/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.81 |
| ▸ | LCK | P06239 | 1/20 | 0.78 |
| ▸ | FES | P07332 | 1/20 | 0.78 |
| ▸ | RET | P07949 | 1/20 | 0.78 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.78 |
| ▸ | KIT | P10721 | 1/20 | 0.78 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.78 |
| ▸ | SRC | P12931 | 1/20 | 0.78 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.78 |
| ▸ | FLT1 | P17948 | 1/20 | 0.78 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.78 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.78 |
| ▸ | KDR | P35968 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3135042 | 1.00 | TNK2 (1.00) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL29875282 | 1.00 | TNK2 (1.00) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL3132435 | 0.96 | TNK2 (0.92) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL3139165 | 0.94 | TNK2 (0.89) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL3132500 | 0.94 | TNK2 (0.88) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL3136175 | 0.93 | TNK2 (0.90) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL3137360 | 0.93 | TNK2 (0.88) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL13521779 | 0.93 | TNK2 (0.93) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL3134169 | 0.93 | TNK2 (1.00) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL3132265 | 0.92 | TNK2 (0.84) | TNK2MAP4K2ABL1BMXBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12104168-B2 | Cell culture medium | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2024-10-01 | — | — | US | claimed |
| CN-114177181-B | Application of GNF-7 in preparation of FLT3 mutant inhibitor | 广州市妇女儿童医疗中心 | 2024-07-12 | — | — | CN | claimed |
| CN-110151767-B | Application of GNF-7 in preparation of medicine for treating influenza virus infection | 武汉威立得生物医药有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-114177181-A | Application of GNF-7 in preparation of FLT3 mutant inhibitor | 广州市妇女儿童医疗中心 | 2022-03-15 | — | — | CN | claimed |
| EP-4105213-B1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME | PHAROS IBIO CO LTD (KR) | 2026-04-15 | — | — | EP | disclosed |
| US-20260078126-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070913-A1 | 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA INST SCI & TECH (KR) | 2026-03-12 | — | — | US | disclosed |
| US-20260070903-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-12 | — | — | US | disclosed |
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-25 | — | — | US | disclosed |
| US-12398145-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-12281301-B2 | Sequencing-based proteomics | THE BROAD INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-110151767-B | Application of GNF-7 in preparation of medicine for treating influenza virus infection | 武汉威立得生物医药有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-110151767-B | Application of GNF-7 in preparation of medicine for treating influenza virus infection | 武汉威立得生物医药有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20220135559-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-05-05 | — | — | US | disclosed |
| WO-2022093742-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-114177181-A | Application of GNF-7 in preparation of FLT3 mutant inhibitor | 广州市妇女儿童医疗中心 | 2022-03-15 | — | — | CN | disclosed |
| CN-114177181-A | Application of GNF-7 in preparation of FLT3 mutant inhibitor | 广州市妇女儿童医疗中心 | 2022-03-15 | — | — | CN | disclosed |
| CN-114177181-A | Application of GNF-7 in preparation of FLT3 mutant inhibitor | 广州市妇女儿童医疗中心 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | CTTN, SRC, FYN | TNK2 27/4885MAP4K2 160/4885ABL1 6/4885 |
| US-20260078126-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK2, SBK3, SIK3 | TNK2 103/4885MAP4K2 230/4885ABL1 2112/4885 |
| US-20220135559-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | CDK8, HASPIN, CDK4 | TNK2 36/4885MAP4K2 46/4885ABL1 1193/4885 |
| US-12398145-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | TNK2 202/4885MAP4K2 80/4885ABL1 1450/4885 |
| US-20260070913-A1 | 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | CSNK1A1, CKS1B, HGFAC | TNK2 28/4885MAP4K2 165/4885ABL1 318/4885 |
| US-20260070903-A1 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | CCNC, CKS1B, CKS2 | TNK2 29/4885MAP4K2 198/4885ABL1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.